Overview

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to determine the safety and efficacy of TNK infusion for the treatment of loculated pleural effusions in patients with known malignancy compared to normal saline infusion.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Kaiser Permanente
Collaborator:
Genentech, Inc.
Treatments:
Tenecteplase
Tissue Plasminogen Activator